Abstract：Objective To study the different molecular typing and clinical features of brain metastases from breast cancer and survival analysis.Methods We retrospectively analyzed the clinical data of 55 patients with brain metastases from breast cancer, according to the Results of immunohistochemistry divided into luminal A, luminal B, human epidermal growth receptor-2(HER-2)＋,and triplenegative. We the analyzed their clinical characteristics, treatment process and survival after diagnosis of brain metastases in the four subtypes of patients.Results Four subtypes median survival after diagnosis of brain metastases in patients with cancer were: 10 (0-49), 8 (1-51), 7 (0-19), 8.5 (0 to 21) months, the difference was not significant, the median overall survival, median disease-free survival, and the median no brain metastasis survival difference were statistically significant between triple-negative disease-free survival shortest, brain metastasis occurred much earlier.Conclusions Once the diagnosis of brain metastases from breast cancer is confirmed, regardless of thmolecular typing survival period is short, there is no ideal treatment, brain metastases from triple-negative easier lead to early breast cancer.
张淼, 胡蓉, 毛志远, 刘亚妮, 樊再雯. 不同分子分型乳腺癌脑转移癌临床特征及其生存分析[J]. 武警医学, 2016, 27(8): 792-795.
ZHANG Miao, HU Rong, MAO Zhiyuan, LIU Yani, and FAN Zaiwen. Different molecular classification brain metastases from breast cancer clinical characteristics and survival analysis. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(8): 792-795.
Dayan A,Koca D,AKman T,et al.The factors that have an impact on the development of brain metastasis in the patients with breast cancer[J].J Cancer Res Ther,2012,8(4):542-548.
[2]
Lekanidi K,Evans A L,Shah J,et al.Pattern of brain metastatic disease according to HER-2 and ER Receptor status in breast cancer patients[J].Clin Radiol,2013,68(10):1070-1073.
[3]
Linskey M E,Andrews D W,Asher A L,et al.The role of stereotactic radiosurgery in the management of pat-Ient with newly diagnosed brain metastases:a systematic review and evidence-based clinical practice guideline[J]. Neurooncol,2011,96(1):45-68.
[4]
Taskar K S,Rudraraju V,Mittapalli R K,et al.Lapatinib distribution in HER2 overexpressing experimental Brain metastases of breast cancer[ J].Pharm Res,2012,29(3):770-781.
[5]
Bachelot T,Romieu G,Campone M,et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastaic breast cancer(LANDSCAPE):A single-group phase 2 study[J].Lancet Oncol,2013,14(1):64-71.
[6]
Kaplan M A,Isikdogan A,Koca D,et al.Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab based therapy:a study by the Anatolian Society of Medical Oncology[J].Beast cancer,2014,21(6):677-683.
[7]
Kim H J,Im S A,Keam B,et al.Clinical outcome of central nervous system metastases from breast cancer:Differences in survival depending on systemic treatment[ J ]. Neurooncol,2012,106(2):303-313.
[8]
Sperduto P W,Kased N,Roberge D,et al.Effect of tumor subtupe on survival and the graded prognostic assessment for patients with breast cancer and brain matastases[J].Int J Rdiat Oncol Biol Phys,2012,82(5):2111-2117.
[9]
Marko N F,Xu Z,Gao T,et al.Predicting survival in woman with breast cancer and brain metastasis:a nomogram outperform current survival prediction models[J].Cancer,2012,118(15):3749-3757.
[10]
Nieder C, Oehlke O, Hintz M, et al. The challenge of durable brain control in patients with brain-only metastases from breast cancer[J].Springerplus,2015, 7(4):585.
[11]
Ricciardi G R, Russo A, Franchina T, et al.Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases[J].Onco Targets Ther,2015 ,2(8):289-294.
[12]
Kuba S, Ishida M, Nakamura Y, et al.Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype[J].Clin Oncol,2014 ,44(11):1025-1031.
[13]
Taskan K S,Rndnavaju V,Mittapalli R K,et al.Lapatinib distribution in HER2 ovenexpressing experimehtal brain metastases of breast cancer[J].Pharm Res,2012,29(3):770-781.
[14]
Bartsch R,Berghoff A,Pluschnig U,et al.Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases[J].Br J cancer,2012,106(1):25-31.
[15]
Niikura N, Hayashi N, Masuda N , et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis[J].Breast Cancer Res Treat,2014,147(1):103-112.
2016, Vol. 27 
